Table 2.
Treatment Effect on Health-related Quality of Life Scores (Generalized Estimating Equation Models, N = 79)
| … | Regression Coefficient | P Value |
|---|---|---|
| [95% CI] | ||
| Physical Component Summary | … | … |
| W16 visit (ref. = W12 visit) | 0.58 [−1.32 to 2.48] | .551 |
| W0 value effect | 0.53 [0.38–0.67] | … |
| Cannabidiol (ref. = placebo) | 1.47 [−1.48 to 4.41] | .329 |
| W16 visit × cannabidiol | −1.32 [−4.04 to 1.41] | .343 |
| Mental Component Summary | … | … |
| W16 visit (ref. = W12 visit) | 0.19 [−2.47 to 2.84] | .891 |
| W0 value effect | 0.67 [0.47–0.87] | <.001 |
| Cannabidiol (ref. = placebo) | −0.19 [−4.42 to 4.04] | .930 |
| W16 visit × cannabidiol | 1.40 [−2.39 to 5.19] | .470 |
| Physical Functioning | … | … |
| W16 visit (ref. = W12 visit) | 1.99 [−1.64 to 5.62] | .283 |
| W0 value effect | 0.61 [0.44–0.78] | <.001 |
| Cannabidiol (ref. = placebo) | 7.72 [0.55–14.89] | .035 |
| W16 visit × cannabidiol | −2.64 [−7.84 to 2.55] | .318 |
| Role Physical | … | … |
| W16 visit (ref. = W12 visit) | −2.88 [−13.36 to 7.60] | .591 |
| W0 value effect | 0.30 [0.14–0.47] | <.001 |
| Cannabidiol (ref. = placebo) | −7.66 [−20.78 to 5.46] | .253 |
| W16 visit × cannabidiol | 6.57 [−8.45 to 21.58] | .391 |
| Bodily Pain | … | … |
| W16 visit (ref. = W12 visit) | 5.41 [−0.16 to 10.98] | .057 |
| W0 value effect | 0.50 [0.33–0.67] | <.001 |
| Cannabidiol (ref. = placebo) | 7.55 [−1.75 to 16.84] | .111 |
| W16 visit × cannabidiol | −9.00 [−16.97 to −1.04] | .027 |
| General Health | … | … |
| W16 visit (ref. = W12 visit) | −0.074 [−4.07 to 3.93] | .971 |
| W0 value effect | 0.76 [0.61–0.91] | <.001 |
| Cannabidiol (ref.=placebo) | 1.09 [−5.57 to 7.56] | .747 |
| W16 visit × cannabidiol | 0.39 [−5.33 to 6.11] | .894 |
| Vitality | … | … |
| W16 visit (ref. = W12 visit) | 0.76 [−4.03 to 5.55] | .755 |
| W0 value effect | 0.65 [0.47–0.83] | <.001 |
| Cannabidiol (ref. = placebo) | 4.43 [−2.30 to 11.16] | .197 |
| W16 visit × cannabidiol | −2.75 [−9.60 to 4.11] | .432 |
| Social Functioning | … | … |
| W16 visit (ref. = W12 visit) | 1.51 [−4.52 to 7.54] | .623 |
| W0 value effect | 0.54 [0.34–0.74] | <.001 |
| Cannabidiol (ref. = placebo) | −0.81 [−10.16 to 8.53] | .865 |
| W16 visit × cannabidiol | 1.32 [−7.31 to 9.94] | .765 |
| Role Emotional | … | … |
| W16 visit (ref. = W12 visit) | 1.97 [−11.41 to 7.47] | .682 |
| W0 value effect | 0.43 [0.26–0.61] | <.001 |
| Cannabidiol (ref. = placebo) | −5.62 [−18.49 to 7.24] | .391 |
| W16 visit × cannabidiol | 10.26 [−3.26 to 23.77] | .137 |
| Mental Health | … | … |
| W16 visit (ref. = W12 visit) | 1.74 [−2.88 to 6.36] | .461 |
| W0 value effect | 0.80 [0.61–0.98] | <.001 |
| Cannabidiol (ref. = placebo) | 4.11 [−2.83 to 11.06] | .246 |
| W16 visit × cannabidiol | −2.27 [−8.88 to 4.34] | .501 |
Models were adjusted for age, sex, CD4/CD8 cell count ratio, and time since the first persistent undetectable viral load.
CI, confidence interval; ref., reference; W, week.